Oruka Therapeutics, Inc. ORKA
Oruka Therapeutics, Inc. (Nasdaq: ORKA) is a dermatology drug developer. Its lead program, ORKA-001, is in Phase 2 for moderate-to-severe plaque psoriasis (EVERLAST-A Phase 2a, EVERLAST-B Phase 2b). Its next catalyst on record is ORKA-001 EVERLAST-B: Week 16 data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ORKA-001 EVERLAST-B — Week 16 data (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ORKA-001 (extended half-life anti-IL-23p19 mAb) | psoriasis (Phase 2a EVERLAST-A: Week 16 PASI 100 in 40 of 63 treated; Phase 2b EVERLAST-B enrolled 187) | antibody | Phase 2 |
| ORKA-002 (extended half-life anti-IL-17A/F mAb) | psoriasis (ORCA-SURGE Phase 2, ~160 pts, started Feb 2026) | antibody | Phase 2 |
| ORKA-002 | hidradenitis suppurativa (ORCA-SPLASH Phase 2, ~160 pts) | antibody | Phase 2 |
| ORKA-004 (anti-TL1A mAb) | combination with ORKA-001/002 in I&I diseases | antibody | Pre-clinical |
| ORKA-003 | undisclosed pathway | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.